Disease-modifying anti-rheumatic drugs

Phase 3Small molecule

Disease-modifying anti-rheumatic drugs is one of 67 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

Rheumatoid ArthritisCompleted

COVID-19Preclinical

Active, not recruiting

Rheumatoid ArthritisPhase 3

Completed

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Disease-modifying anti-rheumatic drugs

Roche

Phase 3

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Calciferol

Activella

Tricor

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Achromycin V

WWyeth-Lederle Vaccines

Statin

1 10

Glucocorticoid

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Completed· Astellas logo

Astellas·Phase 3·NCT03660059·385 enrolled

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01194414·1,262 enrolled

L-carnitine Supplementation in Rheumatoid Arthritis Patients

Recruiting·GGerman University in Cairo·Phase 2·NCT06753565·60 enrolled

Tocilizumab1 trial

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Completed· Roche logo

Roche·Phase 3·NCT00720798·2,067 enrolled

COVID-191 trial

Predictive Factors for COVID-19 in Rheumatology

Unknown status·FFundación Santa Fe de Bogota··NCT04567576·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Disease-modifying anti-rheumatic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Disease-modifying anti-rheumatic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Disease-modifying anti-rheumatic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Disease-modifying anti-rheumatic drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Tocilizumab1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News